BlueCrest Capital Management’s Pfizer PFE Stock Holding History

BlueCrest Capital Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-26,350	Closed	-$739K	–	654
2014 Q3	$739K	Buy	+26,350	New	+$740K	0.03%	372

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BlueCrest Capital Management's PFE Position: Q2 2024 in Review

BlueCrest Capital Management sold out of Pfizer (PFE) in Q2 2024, closing a stake of 87,036 shares — an estimated $2.42M sold.

BlueCrest Capital Management first reported a position in PFE in Q3 2016 and held it in 14 quarters. The position peaked at $15.8M in Q2 2018. 2,873 funds tracked by Wall St. Rank hold PFE as of Q2 2024.

BlueCrest Capital Management reported no remaining Pfizer position as of Q2 2024 after selling out during the quarter.
BlueCrest Capital Management sold 87,036 Pfizer shares in Q2 2024, an estimated $2.42M.
BlueCrest Capital Management first reported a position in Pfizer in Q3 2016 and held it in 14 quarters.
BlueCrest Capital Management's Pfizer position peaked at $15.8M in Q2 2018.
2,873 funds tracked by Wall St. Rank held Pfizer as of Q2 2024.

Based on BlueCrest Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.